Drug · CHEMBL53463
DOXORUBICIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DOXORUBICIN. Drugs and targets, record CHEMBL53463. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL53463
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Adriablastin, Doxorubicina, Doxorubicine, Epirubicin hydrochloride impurity, doxorubicin-, Hydroxydaunorubicin, NSC-123127, NSC-759155, Valrubicin impurity, doxorubicin
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 216 diseases, from ATC and EMA Human Drugs
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | DNA topoisomerase II alpha inhibitor | INHIBITOR | https://conductscience.org/library/genes/7153 |
Source ChEMBL
Diseases216
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Phase 3 | ClinicalTrials.gov | 257 | 255 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 161 | 161 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| ovarian cancer | Phase 3 | ClinicalTrials.gov | 111 | 111 | https://conductscience.org/library/drugs?q=MONDO_0008170 |
| soft tissue sarcoma | Phase 3 | ClinicalTrials.gov | 80 | 80 | https://conductscience.org/library/drugs?q=MONDO_0018078 |
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 71 | 71 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| plasma cell myeloma | Approval | EMA Human Drugs | 72 | 68 | https://conductscience.org/library/drugs?q=MONDO_0009693 |
| Hodgkins lymphoma | Phase 3 | ClinicalTrials.gov | 63 | 63 | https://conductscience.org/library/drugs?q=MONDO_0004952 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 53 | 53 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov and TTD | 50 | 49 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| primary peritoneal carcinoma | Phase 3 | ClinicalTrials.gov | 45 | 45 | https://conductscience.org/library/drugs?q=MONDO_0015686 |
1 to 10 of 216Source Open Targets
See all 216 diseasesTrials1,443
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 26 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 60 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | Phase 3 | 5,351 | 2012-10-31 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | Phase 3 | 4,894 | 2017-12-12 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00312208 | Docetaxel in Breast Cancer | Phase 3 | 3,299 | 2010-02-17 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | Phase 3 | 3,222 | 2016-11-15 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | Phase 3 | 2,722 | 2022-08-11 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | Phase 3 | 2,199 | 2024-08-21 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00493870 | TAC Versus TC for Adjuvant Breast Cancer | Phase 3 | 1,961 | 2023-03-02 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | Phase 3 | 1,925 | 2019-07-12 | doxorubicin | Its name | ClinicalTrials.gov |
| NCT00688740 | Docetaxel in Node Positive Adjuvant Breast Cancer | Phase 3 | 1,491 | 2011-02-14 | doxorubicin | Its name | ClinicalTrials.gov |
1 to 10 of 1,443
See all 1,443 trialsComparisons in its trials248
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) | 356 of 1,649 | 352 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival) | 187 of 1,649 | 202 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events | 331 of 1,634 | 520 of 1,635 | 3,269 | NCT00312208 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 | 72 of 1,101 | 2,199 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE) | 1,074 of 1,084 | 1,090 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 173 of 1,084 | 280 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| TC Arm vs TAC Arm: deaths from any cause | 110 of 969 | 88 of 965 | 1,934 | NCT00493870 | Trial comparisons |
1 to 10 of 248
See all 248 comparisons in its trialsPapers from its trials1,007
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL53463
GET https://conductscience.org/api/drugs/v1/CHEMBL53463/diseases?page=2